<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923312</url>
  </required_header>
  <id_info>
    <org_study_id>CV-9201-003</org_study_id>
    <nct_id>NCT00923312</nct_id>
  </id_info>
  <brief_title>Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Safety and Efficacy Phase I/IIa Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureVac AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CureVac AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/IIa open, uncontrolled, international, prospective clinical trial, in an&#xD;
      out-patient setting, in patients with stage IIIB/IV NSCLC.&#xD;
&#xD;
      The phase I part of the study consists of a dose escalation phase, in which the recommended&#xD;
      dose (RD) for the phase IIa part of the study will be established based on the incidence of&#xD;
      dose-limiting toxicities (DLT). In the phase IIa part of the study, additional patients will&#xD;
      be included at the RD, to confirm the safety and explore the activity of that dose.&#xD;
&#xD;
      This study will take place in Switzerland (2 sites) and Germany (11 sites).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical Need:&#xD;
&#xD;
      Lung cancer is the leading cause of cancer mortality in developed countries; about 87% of&#xD;
      lung cancers are of the NSCLC type. Patients with more advanced but non-metastatic disease&#xD;
      (IIIA or IIIB) usually undergo chemotherapy and/or radiation therapy, with or without&#xD;
      secondary surgical resection. Patients with progression after chemotherapy and/or&#xD;
      radiotherapy may receive second-line treatment with targeted therapies. Despite these&#xD;
      aggressive treatments, only about 5% of patients with metastatic disease survive for 5 or&#xD;
      more years. Given these dismal statistics, it is clear that new therapeutic approaches for&#xD;
      treatment of NSCLC are urgently needed.&#xD;
&#xD;
      Potential Benefits:&#xD;
&#xD;
      CV9201 is an mRNA-based vaccine for the treatment of human NSCLC that is based on CureVac's&#xD;
      RNActive® technology.&#xD;
&#xD;
      As an mRNA-based vaccine, CV9201 features several advantages over other approaches: it is&#xD;
      highly specific, there is no restriction to the patient's MHC genotype, and it does not need&#xD;
      to cross the nuclear membrane to be active. Finally, in the absence of reverse transcriptase,&#xD;
      RNA can not be integrated into the genome.&#xD;
&#xD;
      For the planned first-in-man study, CV9201 will be administered in 5 doses. The phase I part&#xD;
      of this phase I/IIa study is a dose finding study, to determine the RD for the phase IIa&#xD;
      part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determination of the recommended dose (RD) for exploration in the phase IIa part of the study</measure>
    <time_frame>During the first 2-3 month of Phase I</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Assessment of safety and tolerability of the treatment regimen</measure>
    <time_frame>Complete duration of Phase II</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CV9201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CV9201</intervention_name>
    <description>CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.</description>
    <arm_group_label>CV9201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female and age ≥ 18 yrs and ≤ 75&#xD;
&#xD;
          2. Histologically or cytologically confirmed and documented stage IIIB /IV NSCLC&#xD;
&#xD;
          3. Documented stable disease or objective response according to RECIST criteria after&#xD;
             initial chemotherapy or chemo-radiotherapy for advanced, unresectable disease:&#xD;
&#xD;
               -  Patients must have received a minimum of two cycles of standard chemotherapy, and&#xD;
                  adequate and effective radiotherapy if used in conjunction with chemotherapy&#xD;
                  (sequentially or concomitantly). Prophylactic brain radiation is allowed.&#xD;
&#xD;
               -  Surgery, radiotherapy and/ or chemotherapy can have been previously administered&#xD;
                  for non-advanced disease.&#xD;
&#xD;
               -  All therapies must be completed 4 weeks before start of study treatment.&#xD;
&#xD;
          4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0 - 1&#xD;
&#xD;
          5. Life expectancy &gt; 6 months as assessed by the investigator&#xD;
&#xD;
          6. Adequate organ function:&#xD;
&#xD;
               -  Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x&#xD;
                  109/L; lymphocyte count ≥ 1.0 x 109/L; absolute neutrophil count (ANC) ≥ 1.5 x&#xD;
                  109/L; platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times&#xD;
                  upper limit of normal (ULN) (≤ 5 x ULN if hepatic metastases present); bilirubin&#xD;
                  ≤ 1.5 x ULN&#xD;
&#xD;
               -  Renal: Creatinine ≤ 2 mg/ dL and creatinine clearance ≥ 45 mL/ min&#xD;
&#xD;
          7. Patients of child-producing potential must agree to use contraception while enrolled&#xD;
             in the study and for one month after the last immunization&#xD;
&#xD;
          8. Written informed consent must be obtained prior to conducting any study-specific&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of anti-cancer therapy for advanced disease other than initial chemotherapy or&#xD;
             chemo-radiotherapy or surgery&#xD;
&#xD;
          2. Immunotherapy within 4 weeks prior to study enrollment, including cytokines such as&#xD;
             G-CSF, GM-CSF or interferons&#xD;
&#xD;
          3. Treatment with investigational anti-cancer agents during initial therapy for advanced&#xD;
             disease or any investigational agents within 4 weeks prior to study enrollment&#xD;
&#xD;
          4. Concurrent anti-tumor therapy or concurrent immunotherapy such as lectins, unspecific&#xD;
             immunostimulants, etc.&#xD;
&#xD;
          5. Previous anti-cancer immunotherapy comprising RNA-transfected dendritic cells or DNA&#xD;
             vaccines targeting any tumor-associated antigens&#xD;
&#xD;
          6. Concurrent systemic steroids except topical (inhaled, topical, nasal) for the last 28&#xD;
             days, except replacement therapy&#xD;
&#xD;
          7. Concurrent major surgery or planned surgery&#xD;
&#xD;
          8. Prior splenectomy&#xD;
&#xD;
          9. Documented history of active autoimmune disorders requiring systemic immunosuppressive&#xD;
             therapy, (e.g., sarcoidosis, lupus erythematosus, rheumatoid arthritis,&#xD;
             glomerulonephritis or systemic vasculitis), excepting autoimmune thyroiditis with only&#xD;
             thyroid hormone replacement and stable disease &gt; 1 year&#xD;
&#xD;
         10. Primary or secondary immune deficiency&#xD;
&#xD;
         11. Active allergy requiring continuous medication or active infections requiring&#xD;
             anti-infectious therapy&#xD;
&#xD;
         12. Seropositive for HIV, HBV or HCV&#xD;
&#xD;
         13. History of other malignancies over the last 5 years (except basal cell carcinoma of&#xD;
             the skin or carcinoma in situ of the cervix)&#xD;
&#xD;
         14. Uncontrolled medical condition considered as high risk for the treatment with an&#xD;
             investigational drug including unstable diabetes mellitus, vena-cava-syndrome, known&#xD;
             ascites and/or uncontrolled pleural effusion.&#xD;
&#xD;
         15. Brain metastases (symptomatic or asymptomatic) or leptomeningeal involvement&#xD;
&#xD;
         16. Symptomatic congestive heart failure (NYHA 3 and 4); unstable angina pectoris within 6&#xD;
             months prior to enrollment; significant cardiac arrhythmia, history of stroke or&#xD;
             transient ischemic attack&#xD;
&#xD;
         17. History of seizures, encephalitis or multiple sclerosis&#xD;
&#xD;
         18. Gastric ulcer or inflammatory bowel disease or Crohn's disease or ulcerative colitis;&#xD;
             no active diverticulitis&#xD;
&#xD;
         19. Active drug abuse or chronic alcoholism&#xD;
&#xD;
         20. Patients being committed to an institution by virtue of an order issued either by the&#xD;
             judicial or the administrative authorities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Knuth, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsspital Zürich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III, Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik V, Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik I, Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01304</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordwest Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, Medizinische Klinik II</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik II, Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.curevac.com</url>
    <description>Homepage Sponsor</description>
  </link>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

